<DOC>
	<DOCNO>NCT02596555</DOCNO>
	<brief_summary>This prospective , multicenter , multinational , phase IV , interventional single-armed ( management ) trial focus safety , efficacy cost-effectiveness new oral anticoagulant treatment patient acute intermediate-risk PE base validate image ( echocardiographic CT angiographic ) laboratory biomarker ( circulate level cardiac troponins natriuretic peptide ) parameter combination .</brief_summary>
	<brief_title>Low Molecular Weight Heparin 72 Hours Followed Dabigatran Acute Intermediate-Risk Pulmonary Embolism .</brief_title>
	<detailed_description />
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . Age ≥18 year 2 . Objectively confirmed diagnosis acute PE multidetector CT angiography , ventilation/perfusion lung scan , selective invasive pulmonary angiography , accord establish diagnostic criterion , without symptomatic deep vein thrombosis 3 . Absence hemodynamic collapse , decompensation , presentation ; Hemodynamic collapse decompensation 4 . Intermediaterisk category PE severity indicate positive ( score ≥1 ) simplify pulmonary embolism severity index ( sPESI ) , combination presence least one follow criterion presentation : At least one sign RV pressure overload/dysfunction CT angiography echocardiography Signs myocardial injury indicate elevated troponin level Signs ( RV ) failure indicate NTproBNP level &gt; 600 pg/ml baseline . 5 . Ability subject understand character individual consequence clinical trial ; sign date informed consent subject available start specific trial procedure 1 . Pregnancy ( negative serum urine pregnancy test available woman childbearing potential study inclusion ) lactation 2 . Women childbearing potential practice medically accept highly effective contraception trial one month beyond 3 . History hypersensitivity investigational medicinal product drug similar chemical structure excipient present pharmaceutical form investigational medicinal product 4 . Participation another clinical trial present clinical trial within last three month 5 . Medical psychological condition would permit completion trial signing inform consent 6 . Use fibrinolytic agent , surgical thrombectomy , interventional ( catheterdirected ) thrombus aspiration lysis , use cava filter treat index episode PE 7 . Treatment therapeutically dose anticoagulant 48 hour prior enrolment 8 . Need longterm treatment low molecular weight heparin , vitamin K antagonists NOAC , indication index PE episode , antiplatelet agent except acetylsalicylic acid dosage ≤100 mg/day ; 9 . Active bleed know significant bleeding risk ( e.g. , gastrointestinal ulcer , malignant neoplasm , injury recent surgery brain , spinal cord eye , recent intracranial bleeding , know suspect esophagus varix , aneurysms intraspinal intracranial vascular abnormality ) 10 . Artificial heart valves require treatment anticoagulant 11 . Renal insufficiency estimate creatinine clearance &lt; 30 ml/min/1.73m2 12 . Chronic liver disease aminotransferase level two time local upper limit normal range 13 . Concomitant administration strong inhibitor Pglycoprotein like ketoconazole , cyclosporin , itraconazole dronedarone 14 . Unwillingness inability adhere treatment followup visit 15 . Life expectancy le 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>